Last update 08 May 2025

Prospect Therapeutics, Inc.

Dissolved
| Private Company|2006|Massachusetts, United States

Overview

Related

1
Drugs associated with Prospect Therapeutics, Inc.
GCS-100
Target
galectin-3
Mechanism
galectin-3 inhibitors
Active Org.-
Originator Org.-
Active Indication-
Inactive Indication
Chronic Kidney Diseases [+9]
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Prospect Therapeutics, Inc.
ISRCTN66315383
/ CompletedNot Applicable
A phase II study of GCS-100 in combination with chemo-immunotherapy in relapsed or refractory diffuse large B-cell lymphoma
EUCTR2008-004087-40-GB
/ Unknown statusNot Applicable
A Phase 2 Study of GCS-100 in Combination with Chemo-immunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
100 Clinical Results associated with Prospect Therapeutics, Inc.
Login to view more data
0 Patents (Medical) associated with Prospect Therapeutics, Inc.
Login to view more data
100 Deals associated with Prospect Therapeutics, Inc.
Login to view more data
100 Translational Medicine associated with Prospect Therapeutics, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Other
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
GCS-100
 ( galectin-3 )		Chronic Lymphocytic Leukemia
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free